Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClouDr Group's EBITDA for the
six
months ended in Dec. 2025 was HK$-354 Mil.
Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-1,048 Mil.
During the past 3 years, the average EBITDA Growth Rate was 18.00% per year.
During the past 5 years, the average EBITDA Growth Rate was 36.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.
During the past 7 years, the highest 3-Year average EBITDA Growth Rate of ClouDr Group was 59.30% per year. The lowest was -42.50% per year. And the median was 37.60% per year.
ClouDr Group's EBITDA per Share for the
six
months ended in Dec. 2025 was HK$-0.57.
Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-1.73.
During the past 3 years, the average EBITDA per Share Growth Rate was 35.20% per year.
During the past 5 years, the average EBITDA per Share Growth Rate was 38.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.
During the past 7 years, the highest 3-Year average EBITDA per Share Growth Rate of ClouDr Group was 58.70% per year. The lowest was -76.30% per year. And the median was 46.35% per year.
EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.
While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.
The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.
EBITDA can be thought of as the cash a business generates that is available to:
Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners
EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.
A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.
Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.
Be Aware
Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.
EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.
ClouDr Group EBITDA Related Terms
ClouDr Group EBITDA Historical Data
* Premium members only.
The historical data trend for ClouDr Group's EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, ClouDr Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClouDr Group EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ClouDr Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ClouDr Group's EV-to-EBITDA falls into.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ClouDr Group's EBITDA for the fiscal year that ended in Dec. 2025 is calculated as
ClouDr Group's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2025, ClouDr Group's EBITDA was HK$-977 Mil.
ClouDr Group's EBITDA for the quarter that ended in Dec. 2025 is calculated as
ClouDr Group's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2025, ClouDr Group's EBITDA was HK$-354 Mil.
EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1,048 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.
ClouDr Group (HKSE:09955) has a EBITDA of HK$-1,048 Mil as of Dec. 2025. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on ClouDr Group.
Is ClouDr Group's EBITDA too high?
ClouDr Group's current EBITDA is HK$-1,048 Mil. Overall, ClouDr Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's EBITDA compare to MCK and COR?
ClouDr Group's EBITDA of HK$-1,048 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Distribution company?
A good EBITDA depends on the Medical Distribution industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on ClouDr Group. ClouDr Group's current EBITDA is HK$-1,048 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
Based on GuruFocus' analysis, ClouDr Group (HKSE:09955) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.81, compared to a current price of HK$0.51 — trading 37% below its estimated fair value. The current EBITDA is HK$-1,048 Mil. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For ClouDr Group (HKSE:09955), the current EBITDA is HK$-1,048 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClouDr Group (HKSE:09955) Overvalued in 2026?
Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued.
The current stock price of HK$0.51 is trading 37% below its estimated GF Value™ of HK$0.81.
GuruFocus considers ClouDr Group to be Possible Value Trap.
Key valuation signals for HKSE:09955:
EBITDA: HK$-1,048 Mil
GF Value™: HK$0.81 vs. price of HK$0.51 (37% below fair value)
No single metric tells the full story. See the HKSE:09955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score
Get the complete analysis for HKSE:09955
EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09955 has been successfully added to your 
